Symbols / BCDA Stock $1.16 -0.85% BioCardia, Inc.
BCDA (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It also provides CardiALLO, an allogeneic mesenchymal stem cell therapy which is in phase II for ischemic heart failure; allogeneic cell therapy platform; and PulmALLO, an allogeneic mesenchymal stem cell therapy for acute respiratory distress syndrome. In addition, the company offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; Heart3D for fusion imaging; and morph DNA and avance steerable introducers. It has a license and distribution agreement with Biomet Biologics, LLC. BioCardia, Inc. is based in Sunnyvale, California.
Ratings
Current target
$1.16
Low
$6.00
High
$25.00
Mean
$15.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-09-22 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2024-12-18 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2024-11-14 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2024-10-28 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2024-08-21 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2024-08-16 | main | HC Wainwright & Co. | Buy → Buy | $25 |
| 2024-07-26 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2024-05-29 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2023-11-14 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2023-10-11 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2023-09-06 | main | HC Wainwright & Co. | Buy → Buy | $4 |
| 2023-08-10 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2023-07-24 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2023-06-21 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2023-05-11 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2023-03-30 | reit | HC Wainwright & Co. | — → Buy | $9 |
| 2022-11-11 | down | Dawson James | Buy → Neutral | — |
| 2021-12-20 | init | HC Wainwright & Co. | — → Buy | $9 |
| 2021-04-16 | down | Dawson James | Buy → Neutral | — |
| 2020-09-21 | init | Alliance Global Partners | — → Buy | $12 |
- BioCardia CEO Peter Altman buys $1,230 in BCDA stock - Investing.com Wed, 22 Apr 2026 21
- BioCardia (BCDA) CEO Peter Altman adds 1,000 shares in open-market buys - Stock Titan Wed, 22 Apr 2026 21
- BIOCARDIA ($BCDA) Releases Q4 2025 Earnings - Quiver Quantitative ue, 24 Mar 2026 07
- Is BioCardia (BCDA) stock influenced by uncertainty | BioCardia Posts 65.4% EPS Beat With No Q4 Revenue - Crowd Breakout Signals - Cổng thông tin điện tử Tỉnh Sơn La hu, 23 Apr 2026 00
- BCDA (BioCardia Inc.) posts far narrower Q4 2025 loss than estimates, shares dip 0.84% in today’s trading. - ROA - Cổng thông tin điện tử tỉnh Lào Cai hu, 23 Apr 2026 10
- BCDA (BioCardia Inc.) posts far narrower Q4 2025 loss than analyst estimates, shares rise slightly. - AI Stock Signals - Xã Thanh Hà hu, 23 Apr 2026 06
- BioCardia (BCDA) Receives Positive Feedback from Japanese Regula - GuruFocus Mon, 20 Apr 2026 18
- Bullish BioCardia Insider Buying Worth US$1.06m Yet To Pay Off - Yahoo Finance Sat, 20 Sep 2025 07
- BioCardia, Inc. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:BCDA) 2026-03-24 - Seeking Alpha ue, 24 Mar 2026 07
- BioCardia to give corporate update with 2025 results on March 24 - Stock Titan hu, 19 Mar 2026 07
- Japan regulator says BioCardia heart failure therapy data is likely enough - Stock Titan Mon, 20 Apr 2026 12
- Altman Peter buys BioCardia (BCDA) shares worth $1,194 - Investing.com Wed, 21 Jan 2026 08
- Catheter to deliver cell and gene therapies to the heart heads to FDA - Stock Titan ue, 10 Feb 2026 08
- BioCardia (NASDAQ: BCDA) faces Nasdaq notice for stockholders’ equity deficiency - Stock Titan Wed, 15 Apr 2026 20
- Heart failure subgroup saw 47% lower cardiac death as BioCardia heads to FDA - Stock Titan hu, 02 Apr 2026 07
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
-100.00%
|
0.06
-87.84%
|
0.48
-64.72%
|
1.35
|
| Operating Revenue |
|
0.00
-100.00%
|
0.06
-87.84%
|
0.48
-64.72%
|
1.35
|
| Cost Of Revenue |
|
—
|
—
|
—
|
—
|
| Reconciled Cost Of Revenue |
|
—
|
—
|
—
|
—
|
| Gross Profit |
|
—
|
—
|
—
|
—
|
| Operating Expense |
|
8.28
+2.72%
|
8.06
-33.51%
|
12.12
-8.54%
|
13.25
|
| Research And Development |
|
4.96
+13.11%
|
4.39
-43.22%
|
7.73
-12.54%
|
8.83
|
| Selling General And Administration |
|
3.32
-9.69%
|
3.67
-16.45%
|
4.39
-0.54%
|
4.42
|
| Total Expenses |
|
8.28
+2.72%
|
8.06
-33.51%
|
12.12
-8.54%
|
13.25
|
| Operating Income |
|
-8.28
-3.46%
|
-8.00
+31.29%
|
-11.64
+2.16%
|
-11.90
|
| Total Operating Income As Reported |
|
-8.28
-3.46%
|
-8.00
+31.29%
|
-11.64
+2.16%
|
-11.90
|
| EBITDA |
|
-8.25
-4.03%
|
-7.93
+31.37%
|
-11.56
+2.19%
|
-11.82
|
| Normalized EBITDA |
|
-8.25
-4.03%
|
-7.93
+31.37%
|
-11.56
+2.19%
|
-11.82
|
| Reconciled Depreciation |
|
0.02
-64.18%
|
0.07
-20.24%
|
0.08
+2.44%
|
0.08
|
| EBIT |
|
-8.28
-3.46%
|
-8.00
+31.29%
|
-11.64
+2.16%
|
-11.90
|
| Total Unusual Items |
|
—
|
—
|
—
|
—
|
| Total Unusual Items Excluding Goodwill |
|
—
|
—
|
—
|
—
|
| Special Income Charges |
|
—
|
—
|
—
|
—
|
| Net Income |
|
-8.23
-3.55%
|
-7.95
+31.33%
|
-11.57
+2.82%
|
-11.91
|
| Pretax Income |
|
-8.23
-3.55%
|
-7.95
+31.33%
|
-11.57
+2.82%
|
-11.91
|
| Net Non Operating Interest Income Expense |
|
—
|
—
|
—
|
—
|
| Interest Expense Non Operating |
|
—
|
—
|
—
|
—
|
| Net Interest Income |
|
—
|
—
|
—
|
—
|
| Interest Expense |
|
—
|
—
|
—
|
—
|
| Interest Income Non Operating |
|
—
|
—
|
—
|
—
|
| Interest Income |
|
—
|
—
|
—
|
—
|
| Other Income Expense |
|
0.05
-9.09%
|
0.06
-24.66%
|
0.07
+1316.67%
|
-0.01
|
| Other Non Operating Income Expenses |
|
0.05
-9.09%
|
0.06
-24.66%
|
0.07
+1316.67%
|
-0.01
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-8.23
-3.55%
|
-7.95
+31.33%
|
-11.57
+2.82%
|
-11.91
|
| Net Income From Continuing Operation Net Minority Interest |
|
-8.23
-3.55%
|
-7.95
+31.33%
|
-11.57
+2.82%
|
-11.91
|
| Net Income From Continuing And Discontinued Operation |
|
-8.23
-3.55%
|
-7.95
+31.33%
|
-11.57
+2.82%
|
-11.91
|
| Net Income Continuous Operations |
|
-8.23
-3.55%
|
-7.95
+31.33%
|
-11.57
+2.82%
|
-11.91
|
| Normalized Income |
|
-8.23
-3.55%
|
-7.95
+31.33%
|
-11.57
+2.82%
|
-11.91
|
| Net Income Common Stockholders |
|
-8.23
-3.55%
|
-7.95
+31.33%
|
-11.57
+2.82%
|
-11.91
|
| Diluted EPS |
|
-1.23
+57.59%
|
-2.90
+64.59%
|
-8.19
+18.51%
|
-10.05
|
| Basic EPS |
|
-1.23
+57.59%
|
-2.90
+64.59%
|
-8.19
+18.51%
|
-10.05
|
| Basic Average Shares |
|
6.67
+142.98%
|
2.74
+94.32%
|
1.41
+19.52%
|
1.18
|
| Diluted Average Shares |
|
6.67
+142.98%
|
2.74
+94.32%
|
1.41
+19.52%
|
1.18
|
| Diluted NI Availto Com Stockholders |
|
-8.23
-3.55%
|
-7.95
+31.33%
|
-11.57
+2.82%
|
-11.91
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
3.41
-8.35%
|
3.72
+24.67%
|
2.99
-69.50%
|
9.79
|
| Current Assets |
|
2.73
+4.20%
|
2.62
+79.47%
|
1.46
-81.42%
|
7.86
|
| Cash Cash Equivalents And Short Term Investments |
|
2.50
+5.27%
|
2.37
+114.96%
|
1.10
-85.02%
|
7.36
|
| Cash And Cash Equivalents |
|
2.50
+5.27%
|
2.37
+114.96%
|
1.10
-85.02%
|
7.36
|
| Cash Equivalents |
|
—
|
0.00
+0.00%
|
0.00
-99.97%
|
6.89
|
| Cash Financial |
|
2.50
+5.36%
|
2.37
+115.17%
|
1.10
+134.26%
|
0.47
|
| Receivables |
|
0.02
|
0.00
-100.00%
|
0.06
-68.66%
|
0.20
|
| Accounts Receivable |
|
0.02
|
0.00
-100.00%
|
0.06
-68.66%
|
0.20
|
| Gross Accounts Receivable |
|
0.02
|
0.00
-100.00%
|
0.10
-54.25%
|
0.21
|
| Allowance For Doubtful Accounts Receivable |
|
0.00
|
0.00
+100.00%
|
-0.03
-209.09%
|
-0.01
|
| Prepaid Assets |
|
0.22
-13.94%
|
0.25
|
—
|
—
|
| Other Current Assets |
|
—
|
0.25
-14.92%
|
0.29
-1.67%
|
0.30
|
| Total Non Current Assets |
|
0.68
-38.20%
|
1.10
-27.83%
|
1.53
-20.80%
|
1.93
|
| Net PPE |
|
0.51
-45.22%
|
0.93
-31.34%
|
1.36
-22.82%
|
1.76
|
| Gross PPE |
|
1.29
-23.46%
|
1.69
-17.46%
|
2.05
-13.72%
|
2.38
|
| Accumulated Depreciation |
|
-0.79
-3.15%
|
-0.76
-9.65%
|
-0.69
-12.12%
|
-0.62
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Buildings And Improvements |
|
—
|
—
|
—
|
1.59
|
| Machinery Furniture Equipment |
|
0.20
+3.65%
|
0.19
+2.13%
|
0.19
+0.00%
|
0.19
|
| Construction In Progress |
|
—
|
—
|
—
|
0.00
|
| Other Properties |
|
1.07
-27.41%
|
1.47
-19.72%
|
1.84
-15.08%
|
2.16
|
| Leases |
|
0.03
+0.00%
|
0.03
+0.00%
|
0.03
+0.00%
|
0.03
|
| Other Non Current Assets |
|
0.17
+0.00%
|
0.17
+0.00%
|
0.17
+0.00%
|
0.17
|
| Total Liabilities Net Minority Interest |
|
2.52
-12.78%
|
2.89
-37.10%
|
4.59
-6.35%
|
4.90
|
| Current Liabilities |
|
2.43
+4.78%
|
2.32
-35.67%
|
3.61
+0.64%
|
3.58
|
| Payables And Accrued Expenses |
|
1.46
+3.63%
|
1.40
-48.27%
|
2.71
+17.74%
|
2.31
|
| Payables |
|
0.64
+66.49%
|
0.39
-59.94%
|
0.96
+37.09%
|
0.70
|
| Accounts Payable |
|
0.64
+66.49%
|
0.39
-56.74%
|
0.89
+30.31%
|
0.68
|
| Current Accrued Expenses |
|
0.81
-20.12%
|
1.02
-41.87%
|
1.75
+9.29%
|
1.60
|
| Current Debt And Capital Lease Obligation |
|
0.44
+14.81%
|
0.39
+15.62%
|
0.33
+5.71%
|
0.32
|
| Current Capital Lease Obligation |
|
0.44
+14.81%
|
0.39
+15.62%
|
0.33
+5.71%
|
0.32
|
| Current Deferred Liabilities |
|
0.54
+0.56%
|
0.53
-5.17%
|
0.56
-41.87%
|
0.96
|
| Current Deferred Revenue |
|
0.54
+0.56%
|
0.53
-5.17%
|
0.56
-41.87%
|
0.96
|
| Total Non Current Liabilities Net Minority Interest |
|
0.09
-84.81%
|
0.57
-42.36%
|
0.98
-25.38%
|
1.32
|
| Long Term Debt And Capital Lease Obligation |
|
0.09
-84.81%
|
0.57
-42.36%
|
0.98
-25.38%
|
1.32
|
| Long Term Capital Lease Obligation |
|
0.09
-84.81%
|
0.57
-42.36%
|
0.98
-25.38%
|
1.32
|
| Stockholders Equity |
|
0.90
+6.93%
|
0.84
+152.21%
|
-1.60
-132.77%
|
4.89
|
| Common Stock Equity |
|
0.90
+6.93%
|
0.84
+152.21%
|
-1.60
-132.77%
|
4.89
|
| Capital Stock |
|
0.01
+120.00%
|
0.01
+150.00%
|
0.00
-90.00%
|
0.02
|
| Common Stock |
|
0.01
+120.00%
|
0.01
+150.00%
|
0.00
-90.00%
|
0.02
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
10.76
+133.77%
|
4.60
+191.61%
|
1.58
+17.88%
|
1.34
|
| Ordinary Shares Number |
|
10.76
+133.77%
|
4.60
+191.61%
|
1.58
+17.88%
|
1.34
|
| Additional Paid In Capital |
|
169.23
+5.14%
|
160.95
+6.90%
|
150.57
+3.50%
|
145.48
|
| Retained Earnings |
|
-168.35
-5.14%
|
-160.12
-5.22%
|
-152.18
-8.23%
|
-140.60
|
| Total Equity Gross Minority Interest |
|
0.90
+6.93%
|
0.84
+152.21%
|
-1.60
-132.77%
|
4.89
|
| Total Capitalization |
|
0.90
+6.93%
|
0.84
+152.21%
|
-1.60
-132.77%
|
4.89
|
| Working Capital |
|
0.30
-0.33%
|
0.30
+114.02%
|
-2.15
-150.18%
|
4.28
|
| Invested Capital |
|
0.90
+6.93%
|
0.84
+152.21%
|
-1.60
-132.77%
|
4.89
|
| Total Debt |
|
0.53
-44.48%
|
0.95
-27.68%
|
1.31
-19.37%
|
1.63
|
| Capital Lease Obligations |
|
0.53
-44.48%
|
0.95
-27.68%
|
1.31
-19.37%
|
1.63
|
| Net Tangible Assets |
|
0.90
+6.93%
|
0.84
+152.21%
|
-1.60
-132.77%
|
4.89
|
| Tangible Book Value |
|
0.90
+6.93%
|
0.84
+152.21%
|
-1.60
-132.77%
|
4.89
|
| Duefrom Related Parties Current |
|
—
|
—
|
—
|
—
|
| Dueto Related Parties Current |
|
—
|
0.00
-100.00%
|
0.07
+294.44%
|
0.02
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-7.44
+5.71%
|
-7.89
+20.93%
|
-9.97
+5.56%
|
-10.56
|
| Cash Flow From Continuing Operating Activities |
|
-7.44
+5.71%
|
-7.89
+20.93%
|
-9.97
+5.56%
|
-10.56
|
| Net Income From Continuing Operations |
|
-8.23
-3.55%
|
-7.95
+31.33%
|
-11.57
+2.82%
|
-11.91
|
| Depreciation Amortization Depletion |
|
0.02
-64.18%
|
0.07
-20.24%
|
0.08
+2.44%
|
0.08
|
| Depreciation |
|
0.02
-64.18%
|
0.07
-20.24%
|
0.08
+2.44%
|
0.08
|
| Depreciation And Amortization |
|
0.02
-64.18%
|
0.07
-20.24%
|
0.08
+2.44%
|
0.08
|
| Stock Based Compensation |
|
0.43
-41.97%
|
0.74
-28.06%
|
1.03
-12.93%
|
1.18
|
| Provisionand Write Offof Assets |
|
0.00
+100.00%
|
-0.03
-247.83%
|
0.02
|
—
|
| Asset Impairment Charge |
|
—
|
—
|
—
|
0.29
|
| Operating Gains Losses |
|
0.48
-0.21%
|
0.48
+45.62%
|
0.33
+12.20%
|
0.29
|
| Gain Loss On Sale Of PPE |
|
0.48
-0.21%
|
0.48
+45.62%
|
0.33
+12.20%
|
0.29
|
| Change In Working Capital |
|
-0.14
+88.04%
|
-1.20
-1027.13%
|
0.13
+160.28%
|
-0.21
|
| Change In Receivables |
|
-0.02
-120.62%
|
0.10
-15.65%
|
0.12
+312.96%
|
-0.05
|
| Changes In Account Receivables |
|
-0.02
-120.62%
|
0.10
-15.65%
|
0.12
+312.96%
|
-0.05
|
| Change In Inventory |
|
—
|
—
|
—
|
—
|
| Change In Prepaid Assets |
|
0.04
-20.45%
|
0.04
+780.00%
|
0.01
-96.93%
|
0.16
|
| Change In Payables And Accrued Expense |
|
0.34
+140.05%
|
-0.85
-228.23%
|
0.67
+58.57%
|
0.42
|
| Change In Accrued Expense |
|
0.18
+133.27%
|
-0.54
-211.62%
|
0.48
+15.87%
|
0.42
|
| Change In Payable |
|
0.16
+151.58%
|
-0.32
-271.74%
|
0.18
+4500.00%
|
0.00
|
| Change In Account Payable |
|
0.16
+151.58%
|
-0.32
-271.74%
|
0.18
+4500.00%
|
0.00
|
| Change In Other Working Capital |
|
—
|
—
|
-0.34
+32.61%
|
-0.51
|
| Change In Other Current Assets |
|
—
|
—
|
—
|
—
|
| Change In Other Current Liabilities |
|
-0.50
-3.52%
|
-0.48
-52.85%
|
-0.32
-33.33%
|
-0.24
|
| Investing Cash Flow |
|
-0.01
-16.67%
|
-0.01
+50.00%
|
-0.01
+82.86%
|
-0.07
|
| Cash Flow From Continuing Investing Activities |
|
-0.01
-16.67%
|
-0.01
+50.00%
|
-0.01
+82.86%
|
-0.07
|
| Net PPE Purchase And Sale |
|
-0.01
-16.67%
|
-0.01
+50.00%
|
-0.01
+82.86%
|
-0.07
|
| Purchase Of PPE |
|
-0.01
-16.67%
|
-0.01
+50.00%
|
-0.01
+82.86%
|
-0.07
|
| Capital Expenditure |
|
-0.01
-16.67%
|
-0.01
+50.00%
|
-0.01
+82.86%
|
-0.07
|
| Financing Cash Flow |
|
7.57
-17.38%
|
9.16
+145.84%
|
3.73
-27.25%
|
5.12
|
| Cash Flow From Continuing Financing Activities |
|
7.57
-17.38%
|
9.16
+145.84%
|
3.73
-27.25%
|
5.12
|
| Net Issuance Payments Of Debt |
|
—
|
—
|
—
|
—
|
| Issuance Of Debt |
|
—
|
—
|
—
|
—
|
| Long Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Net Long Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Net Common Stock Issuance |
|
8.69
-17.65%
|
10.55
+140.47%
|
4.39
-20.79%
|
5.54
|
| Proceeds From Stock Option Exercised |
|
0.01
|
0.00
|
—
|
0.00
|
| Net Other Financing Charges |
|
-1.13
+19.04%
|
-1.39
-110.27%
|
-0.66
-58.37%
|
-0.42
|
| Changes In Cash |
|
0.12
-90.14%
|
1.27
+120.26%
|
-6.26
-13.63%
|
-5.51
|
| Beginning Cash Position |
|
2.37
+114.96%
|
1.10
-85.02%
|
7.36
-42.80%
|
12.87
|
| End Cash Position |
|
2.50
+5.27%
|
2.37
+114.96%
|
1.10
-85.02%
|
7.36
|
| Free Cash Flow |
|
-7.44
+5.69%
|
-7.89
+20.97%
|
-9.99
+6.07%
|
-10.63
|
| Common Stock Issuance |
|
8.69
-17.65%
|
10.55
+140.47%
|
4.39
-20.79%
|
5.54
|
| Issuance Of Capital Stock |
|
8.69
-17.65%
|
10.55
+140.47%
|
4.39
-20.79%
|
5.54
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-04-22 View
- 8-K2026-04-20 View
- 8-K2026-04-15 View
- 8-K2026-04-02 View
- 42026-03-26 View
- 8-K2026-03-24 View
- 10-K2026-03-24 View
- 8-K2026-03-17 View
- 8-K2026-03-03 View
- 8-K2026-02-10 View
- 42026-02-04 View
- 8-K2026-02-03 View
- 42026-01-21 View
- 42025-12-17 View
- 8-K2025-12-16 View
- 42025-12-10 View
- 42025-12-10 View
- 42025-12-10 View
- 42025-12-10 View
- 42025-12-10 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|